FilingReader Intelligence
Humanwell Healthcare changes control to China Merchants Group
July 31, 2025 at 05:12 PM UTC•By FilingReader AI
Humanwell Healthcare's controlling shareholder changed to China Merchants Life Science (Wuhan) following a share transfer, with China Merchants Group becoming the de facto controller effective July 30, 2025.
The company appointed Deng Weidong as chairman and Du Wentao as general manager. Humanwell also received approval for its female contraceptive drug, drospirenone and ethinyl estradiol tablets, on July 28, 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Hunan Pharmaceutical Announcement on the completion of the re-election of the board of directors and the appointment of senior management personnel and a representative for securities affairsJuly 31, 2025 at 08:00 AM UTC
Announcement by Humanwell Healthcare concerning the receipt of the drug registration certificate for drospirenone and estetrol tabletsJuly 31, 2025 at 08:00 AM UTC
SSE:600079•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Humanwell Healthcare Group publishes news
Free account required • Unsubscribe anytime